AstraZeneca

The White House says the U.S. will begin sharing its entire stock of AstraZeneca COVID-19 vaccines with the world once it clears federal safety reviews

With three coronavirus vaccines now approved in the U.S., what is the difference between the vaccines and should you opt for one over the other?

Canada’s National Advisory Committee on Immunization suspended the Oxford-AstraZeneca coronavirus vaccine for people under the age of 55 on Monday after reports of potential blood clots in users.

Public health voice and former FDA Associate Commissioner Peter Pitts explains the latest on Joe Biden’s search for a new FDA head, and the AstraZeneca vaccine, which saw an issue in its trial data this week.

Clinical trial data for the AstraZeneca vaccine showed 100% effectiveness at preventing death and hospitalizations from COVID-19, but a federal review board express concern that the data was outdated. NBC News medical expert Dr. Natalie Azar says she’s still optimistic about the efficacy of the AstraZeneca shot and explains why.

NIAID Director Dr. Anthony Fauci says the Food and Drug Administration will “place a great deal of scrutiny” on data from the AstraZeneca COVID-19 trial.

AstraZeneca says its coronavirus vaccine developed with the University of Oxford was found to be safe and effective in trials conducted in the U.S., Peru and Chile.

Here’s what we know about each of the coronavirus vaccines, and where they’re being distributed.

Miami-Dade Mayor Daniella Levine Cava announces that county-run COVID-19 vaccine sites will drop eligibility to 40 and older on March 29.

The suspension of the AstraZeneca vaccine in several European countries over the past week could fuel skepticism about the shot far beyond their shores, potentially threatening the rollout of a vaccine that is key to the global strategy to stamp out the coronavirus pandemic

The U.S. is finalizing plans to send a combined 4 million doses of the AstraZeneca COVID-19 vaccine to Mexico and Canada in its first export of shots

The European Union’s drug regulatory agency says the AstraZeneca vaccine doesn’t increase the overall risk of blood clots and that the benefits of using it outweigh the risks

The European Union’s drug regulatory agency says experts have concluded the AstraZeneca vaccine is not linked to an overall increase in the risk of blood clots

The European Union’s drug regulator is insisting that there is “no indication” the AstraZeneca vaccine causes blood clots as governments around the world faced the grimmest of dilemmas: push on with a vaccine known to save lives or suspend its use over reports of clotting in some recipients

The AstraZeneca COVID-19 vaccine has been suspended by some European countries after blood clots were reported in some patients who received it. Regulators are now working to determine if those clots were due to the vaccine or just coincidental. Dr. Michelle McMurry-Heath, an immunologist and CEO of the Biotechnology Innovation Organization, explains how the AstraZeneca differs from the other available...

The World Health Organization’s chief scientist Soumya Swaminathan spoke on Tuesday after several nations made the decision to halt use of the AstraZeneca COVID-19 vaccine.

Germany, France, Italy and Spain have become the latest countries to suspend use of AstraZeneca’s COVID-19 vaccine over reports of dangerous blood clots in some recipients, though the company and European regulators have said there is no evidence the shot is to blame

In recent days, countries including Denmark, Ireland, and Thailand have temporarily suspended their use of AstraZeneca’s coronavirus vaccine after reports that some people who got a dose developed blood clots, even though there’s no evidence that the shot was responsible

Irish health officials have recommended the temporary suspension of the AstraZeneca vaccine after reports of serious blood clotting after inoculations in Norway.

Britain’s main doctors’ organization says it is concerned about the U.K.’s decision to give people a second dose of coronavirus vaccine up to 12 weeks after the first, rather than the shorter gap recommended by manufacturers and the World Health Organization